Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 356

1.

Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.

González FE, Ramírez M, Allerbring EB, Fasching N, Lundqvist A, Poschke I, Achour A, Salazar-Onfray F.

Immunobiology. 2014 Mar;219(3):189-97. doi: 10.1016/j.imbio.2013.10.002. Epub 2013 Oct 12.

PMID:
24192537
2.

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al.

J Immunol. 1995 Mar 1;154(5):2257-65.

PMID:
7868898
3.

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Kärre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R.

Cancer Res. 1997 Oct 1;57(19):4348-55.

4.

Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA.

J Immunol. 1998 Dec 15;161(12):6985-92.

6.

Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.

Viret C, Davodeau F, Guilloux Y, Bignon JD, Semana G, Breathnach R, Jotereau F.

Eur J Immunol. 1993 Jan;23(1):141-6.

PMID:
8419164
7.

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.

Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N.

J Immunol. 2003 Dec 1;171(11):6283-9.

8.

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y.

J Immunol. 1996 Sep 15;157(6):2539-48.

PMID:
8805655
9.
10.

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.

Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.

J Immunol. 1998 Dec 15;161(12):6956-62. Erratum in: J Immunol 1999 Jul 15;163(2):1093.

11.

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.

Cancer Res. 1997 Feb 15;57(4):735-41.

12.

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA.

J Immunol. 1995 Apr 15;154(8):3961-8.

PMID:
7706734
13.

Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.

J Immunol. 1998 Feb 15;160(4):1750-8.

14.

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G.

J Exp Med. 1993 Apr 1;177(4):989-98.

15.

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.

Cancer Res. 1995 Nov 1;55(21):4972-9.

16.

Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.

Wankowicz-Kalinska A, Mailliard RB, Olson K, Graham F, Edington H, Kirkwood JM, Martinek S, Das PK, Storkus WJ.

Melanoma Res. 2006 Apr;16(2):165-74.

PMID:
16567972
17.

Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.

Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG.

J Immunol. 1993 Oct 15;151(8):4209-20.

PMID:
8409397
18.

An antigen-targeted approach to adoptive transfer therapy of cancer.

Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.

Cancer Res. 1999 May 1;59(9):2167-73.

19.

Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.

Maeurer MJ, Hurd S, Martin DM, Storkus WJ, Lotze MT.

Cancer J Sci Am. 1995 Jul-Aug;1(2):162-70.

PMID:
9166469
20.

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.

Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D.

J Immunol. 2000 Dec 15;165(12):7253-61.

Supplemental Content

Support Center